SCIEX introduces new X500B QTOF MS system for biotherapeutic analyses

24 January 2017 (Last Updated January 24th, 2017 18:30)

Life science analytical technologies company SCIEX has introduced the X500B QTOF system for standardised biotherapeutic characterisation.

Life science analytical technologies company SCIEX has introduced the X500B QTOF system for standardised biotherapeutic characterisation.

The new system expands the firm's current X-Series Quadrupole Time of Flight (QTOF) mass spectrometry (MS) platform.

X500B QTOF features an integrated LC-MS solution with SCIEX OS Software interface and  BioPharmaView 2.0 processing software, claimed to be ideal for experts and novices alike by eliminating the necessity for complex setup and intensive sofware.

"The introduction of X500B system brings a new level of simplicity, robustness and integration to simplify the complex world of biologics characterisation."

The system was designed to offer high resolution standardised workflows for biotherapeutic developers, who characterise biologic products in large numbers during the development process.

In 2015, the firm launched the LC-MS solution for routine food, environmental and forensic analysis called X500R QTOF system, which was custom made with easy to use software, methods and libraries.

SCIEX Pharmaceutical/CRO Business senior director Farzana Azam said: “Mass spec users have been asking for systems that are purpose built for their application, and SCIEX has listened.

“The introduction of X500B system brings a new level of simplicity, robustness and integration to simplify the complex world of biologics characterisation.

"The combination of this innovative true benchtop QTOF system and software like SCIEX OS, and unique SWATH Acquisition, creates the complete easy-to-use and streamlined solution for standard biologic analyses.”

The BioPharmaView Software 2.0 of the new system allows easy complex data processing and simple interpretation of SWATH 2.0 data independent acquisition, which provides peptide mapping data from just single injection with high-resolution MS and MSMS data.

This process of peptide mapping data extraction ensures detection of low abundance peptides and post-translational modifications.